Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Healthtrust
Fish and Richardson
Johnson and Johnson
Argus Health
Colorcon
Deloitte
Mallinckrodt
Federal Trade Commission
Farmers Insurance

Generated: January 17, 2018

DrugPatentWatch Database Preview

Levocetirizine dihydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for levocetirizine dihydrochloride and what is the scope of levocetirizine dihydrochloride freedom to operate?

Levocetirizine dihydrochloride
is the generic ingredient in three branded drugs marketed by Apotex Inc, L Perrigo Co, Silarx Pharms Inc, Taro Pharm Inds, Sanofi-aventis Us, Allied Pharma Inc, Dr Reddys Labs Ltd, Glenmark Generics, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Sandoz, Sciegen Pharms Inc, Sun Pharm Inds Ltd, Sun Pharma Global, Synthon Pharms, and Teva Pharms, and is included in twenty-one NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Levocetirizine dihydrochloride has thirty patent family members in twenty-four countries.

There are thirteen drug master file entries for levocetirizine dihydrochloride. Thirty suppliers are listed for this compound.
Summary for levocetirizine dihydrochloride
Pharmacology for levocetirizine dihydrochloride

US Patents and Regulatory Information for levocetirizine dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sciegen Pharms Inc LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 203646-001 Sep 9, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Apotex Inc LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride SOLUTION;ORAL 202915-001 Aug 21, 2014 AA RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 090486-001 Mar 26, 2013 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Macleods Pharms Ltd LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 205564-001 Jan 11, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Apotex Inc LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 203027-001 Feb 13, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allied Pharma Inc LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 202046-001 Sep 17, 2013 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glenmark Generics LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 090385-001 Feb 24, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Dr Reddys Labs Ltd LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride TABLET;ORAL 090392-001 Feb 24, 2011 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Taro Pharm Inds LEVOCETIRIZINE DIHYDROCHLORIDE levocetirizine dihydrochloride SOLUTION;ORAL 202673-001 Jul 26, 2013 AA RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for levocetirizine dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride SOLUTION;ORAL 022157-001 Jan 28, 2008 ➤ Subscribe ➤ Subscribe
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 ➤ Subscribe ➤ Subscribe
Sanofi-aventis Us XYZAL levocetirizine dihydrochloride TABLET;ORAL 022064-001 May 25, 2007 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for levocetirizine dihydrochloride

Supplementary Protection Certificates for levocetirizine dihydrochloride

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
01C/045 Belgium ➤ Subscribe PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
00085 Netherlands ➤ Subscribe PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Healthtrust
Teva
Express Scripts
Farmers Insurance
Chinese Patent Office
Mallinckrodt
Cerilliant
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot